GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients ...
Bone Marrow Donors Can Be Hard to Find. One Company Is Turning to Cadavers
San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...
EurekAlert!1d
Sylvester Cancer researchers share findings in oral presentations at the ASH 2024 Annual Meeting & Exposition
Research findings from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami ...
Yahoo Finance1d
Servier to Present Data Across its Hematology Portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting
Data presentations will focus on the company's clinical and preclinical studies in IDH-mutated acute myeloid leukemia (AML) ...
Business Insider22h
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
and we are particularly excited to announce the updated SLS009 Phase 2a data at ASH in December and to provide topline data from cohorts four and five in patients with relapsed/refractory (R/R) acute ...
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax ...
EurekAlert!7d
ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2024
Researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and PrECOG, LLC, will present a variety of abstracts that aim to improve treatments for patients with lymphoma and acute leukemias at ...
Nasdaq9d
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
"The data being presented this year at ASH demonstrate Syndax's commitment ... patients with R/R mutant nucleophosmin (mNPM1) acute myeloid leukemia (AML). Topline data is expected in the fourth ...
Nasdaq8d
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML ...
Morningstar9d
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
Copies of the abstracts are now available online on the ASH website ... in patients with R/R mutant nucleophosmin (mNPM1) acute myeloid leukemia (AML). Topline data is expected in the fourth ...
Morningstar8d
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid ... at the 66th American Society of Hematology ...
Stockhouse9d
Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting
Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...